World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

PlateletDiagnostics Announces Novel Immune-Based Platelet Function Assay to Monitor Antiplatelet Therapy

Cision PR Newswire by Cision PR Newswire
April 6, 2026
in Press Releases - Lifestyle
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

WATERTOWN, Mass., April 6, 2026 /PRNewswire/ — PlateletDiagnostics, LLC (PlateletDx.com) today announced the development of a first-in-class platelet function assay that measures phosphorylation of the abundant platelet protein, dynamin-related protein 1 (Drp1) using a simple ELISA format that offers a practical alternative to traditional aggregation-based tests for monitoring antiplatelet therapy. The technology, licensed from Beth Israel Deaconess Medical Center (BIDMC), is supported by a recent publication in Blood demonstrating that Drp1 phosphorylation provides a robust platform for immune-based platelet function testing.


PltDxLogo

Current platelet function assays rely on light transmission aggregometry or proprietary cartridge-based systems, which require specialized expertise, dedicated instruments, and expensive consumables that limit their use in routine clinical practice. PlateletDiagnostics’ assay is performed on standard laboratory ELISA equipment, processes whole blood samples, and is designed to fit seamlessly into existing laboratory workflows. This approach enables laboratories to freeze, batch and later analyze samples, reducing technician time and overall cost compared with competing methods.

The new assay leverages dual-site phosphorylation of Drp1, a highly abundant platelet GTPase whose phosphorylation state changes in response to both platelet agonists and antiplatelet agents. Using proprietary antibodies developed by PlateletDiagnostics, the ELISA provides a sensitive readout of platelet reactivity that was shown to perform comparably to aggregometry and point-of-care tests in clinical studies of aspirin and clopidogrel therapy. Because Drp1 integrates signals from multiple pathways, the platform can be adapted to interrogate platelet function in a broad range of clinical scenarios where platelet reactivity is important.

“Antiplatelet medications are prescribed to millions of patients to prevent heart attacks and strokes, but we lack an inexpensive, scalable way to monitor whether individual patients are adequately inhibited or resistant to therapy,” said Robert Flaumenhaft, MD, PhD, Professor of Medicine and Chief of the Division of Hemostasis and Thrombosis at BIDMC, and co-founder of PlateletDiagnostics. “By bringing a platelet function test onto standard ELISA platforms, we aim to make antiplatelet monitoring accessible to any hospital laboratory, not just specialized centers.”

In proof-of-principle clinical studies, the Drp1 phosphorylation ELISA tracked reductions and recovery of platelet function during initiation and washout of aspirin and clopidogrel therapy, demonstrating sensitivity and specificity comparable to or better than established assays. The assay maintained signal stability under conditions that commonly degrade other platelet markers and showed enhanced dynamic range and signal-to-noise relative to cartridge-based tests. These features, together with low per-test cost and compatibility with existing lab infrastructure, position the technology as a scalable solution for large patient populations receiving antiplatelet drugs.

“PlateletDiagnostics is building a platform around post-translational modification–based diagnostics, starting with Drp1 for platelet function,” said Michael Cerio, interim CEO of PlateletDiagnostics. “We believe this simple antibody-based testing approach has the potential to streamline how clinicians manage antiplatelet therapy by delivering rapid, actionable information using tools labs already run at scale, while opening a path to additional platelet and cell-function indications over time.”

PlateletDiagnostics is currently advancing the assay through further clinical validation and exploring options to support regulatory submission and commercialization. The company’s proprietary antibodies and assay design are covered by intellectual property licensed from BIDMC, with additional company-developed reagents supporting a differentiated competitive position in platelet diagnostics.

About PlateletDiagnostics, LLC
Founded by leaders in platelet biology at Harvard Medical School, PlateletDiagnostics is a privately held company developing next-generation platelet function diagnostics positioned to address major unmet needs in antiplatelet monitoring and platelet function testing. By combining immune-based detection with standard laboratory platforms, the company delivers sensitive, convenient, and cost-effective assays.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/plateletdiagnostics-announces-novel-immune-based-platelet-function-assay-to-monitor-antiplatelet-therapy-302734818.html

SOURCE PlateletDiagnostics, LLC

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • How to Go 2x Long Anthropic (ANT): Leverage Shares by Themes Explains ANUU, the 2x Leveraged Anthropic ETF Launching Monday

    0 shares
    Share 0 Tweet 0
  • Mendez & Sanchez Finds Three Counties Accounted for Nearly Two-Thirds of California Rideshare Trips

    0 shares
    Share 0 Tweet 0
  • Highmark Health Reports Revenue of $26.5 billion, $741 million in Operating Income, for Nine Months ended Sept. 30, 2026

    0 shares
    Share 0 Tweet 0
  • AZ Blue Health Choice Expands Access to Resources for Page Families

    0 shares
    Share 0 Tweet 0
  • Payoneer Receives OCC Conditional Approval to Form Stablecoin National Trust Bank

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler